Clinical Trial Finds Psilocybin Eases Depression in Cancer Patients

Recent clinical trial results have demonstrated that a single dose of psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, can offer long-lasting relief from depression and anxiety for individuals battling cancer. The study, published in the journal Cancer, involved 28 patients diagnosed with cancer and major depressive disorder. Participants received psychological support before, during, and after administering a 25-mg dose of psilocybin.

Follow-up assessments conducted two years later revealed significant benefits: over half of the patients experienced substantial reductions in depression, with nearly half maintaining remission. Additionally, about 43% of patients showed decreased anxiety levels. The findings suggest that psilocybin can have enduring antidepressant effects following just a single dose.

An ongoing double-blind trial is now exploring whether up to two doses of psilocybin at 25 mg can further improve outcomes in depression and anxiety among cancer patients. This larger study aims to determine if repeated dosing can increase the rate of remission.

Lead researcher Dr. Manish Agrawal from Sunstone Therapies highlighted the potential of psilocybin, noting that it could become a valuable treatment option for depression in cancer patients if further studies confirm these promising results. The research builds on previous work indicating the long-term mental health benefits of psilocybin, and ongoing investigations may pave the way for its broader use in supportive cancer care.